Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell

AUSTIN, Texas, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ:VRML), a bioanalytical-based women’s health company focused on gynecologic disease, will ring the NASDAQ closing bell today. 

“September is an opportunity for us to reach more women and raise awareness around ovarian cancer,” said Valerie Palmieri, President and CEO of Vermillion, Inc.   “We are working every day to change the status quo and lead the charge in better, and earlier, detection of ovarian cancer. Every 37 minutes a woman dies from ovarian cancer. Close to 40 patients lose the battle per day. Ovarian cancer is also the only gender specific cancer with greater than a 50% mortality rate over 5 years.”

Vermillion’s proprietary technologies, OVA1®, and Overa are FDA-cleared blood tests to evaluate cancer risk in a pelvic mass, helping healthcare providers and women assess risk prior to surgery.  It is well documented that women with high risk of cancer can improve their survival rate by up to 40% by getting to a gynecologic oncologist for the first surgery and today 2/3 of women do not use the right specialist. OVA1® is now included in the American College of Obstetricians and Gynecologists (ACOG) clinical management guidelines for management of pelvic masses and has positive position statements from the National Comprehensive Cancer Network (NCCN) and Society of Gynecologic Oncology (SGO), as well as payer coverage of 40% of the population in the US.  OVA1® is the only test available today capable of accurately assessing all ages, ethnicities, stages and all subtypes of ovarian cancer.

The closing bell ceremony will begin at approximately 3:45pm EDT.  A livestream of the Nasdaq Closing Bell will be available at or

 Visit our website for more information about our products at 

About Vermillion, Inc. 

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.

Investor Relations Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: 617-535-7742